Close Menu

NEW YORK – Abbott reported Wednesday that its 2020 third quarter Diagnostics business revenues rose 38 percent year over year, due to sales of its COVID-19 portfolio.

For the three months ended Sept. 30, the Abbott Park, Illinois-based firm reported overall revenues of $8.85 billion, up nearly 10 percent on a reported basis from $8.08 billion a year ago and beating the consensus Wall Street estimate of $8.51 billion. The firm said that its organic sales, excluding the impact of foreign exchange, grew 11 percent year over year.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

A Harvard-led team reprogrammed DNA methylation patterns of mice with eye problems to restore their sight, AFP reports.

A man in India is suing the Serum Institute of India, saying that he suffered serious side effects from a vaccine it is testing, but the institute has rejected those claims, the Economic Times reports.

The New York Times reports Moderna is planning a clinical trial of its SARS-CoV-2 vaccine in children.

In Nature this week: Readfish tool for targeted nanopore sequencing, genomic diversity of barley and wheat, and more.